European Journal of Molecular & Clinical Medicine

Abstract

Background: To assess efficacy of nebulized magnesium sulphate in Bronchiolitis.
Materials and Methods: Seventy- two patients age ranged 1 month to 24 months of acute bronchiolitis were divided into 2 groups of 36 each. Group I received nebulization with 3 mL of 3.2% magnesium sulphate (MgSO4) every 4 hourly for 24 hours and group I received standard care alone. Parameters such as BSS, respiratory rate (RR), peripheral capillary oxygen saturation (SpO2), heart rate (HR) were recorded before treatment and at 1, 2, 4, 8, 12, 16, and 24 hours post- operatively. The need for noninvasive ventilation, need for admission to intensive care unit (ICU) were also recorded.
Results: Group I had 20 males and 16 females and group II had 18 males and 18 females. Duration of illness (days) was 4.6 and 3.4, heart rate (beats/min) was 172.4 and 150.2, respiratory rate (breaths/min) was 56.2 and 54.8, oxygen saturation (%) was 95.2 and 96.4, temperature (degree F) was 98.2 and      99.0, oxygen requirement (L/min) was 1.54 and 1.20 and BSS was 6.72            and 6.24 in group I and II respectively. The difference was non- significant (P> 0.05). BASS at 1 hour was 6.4 and 5.6, at 2 hours was 5.2 and 5.4, at 4 hours was 4.1 and 4.3, at 8 hours was 3.6 and 3.2, at 12 hours was 3.4 and 3.1, at 16 hours was 3.1 and 2.5 and at 24 hours was 2.5 and 2.2. Length of hospital stay was 2.87 days and 2.91 days and duration of oxygen requirement was 25.7 hours and 21.3 hours in group I and II respectively. ICU admission was among 2 in group I and 1 in group II and NIV requirement was seen in 3 in group I and 2 in group II. The difference was non- significant (P> 0.05).
Conclusion: Nebulized magnesium sulfate was comparable with standard care. However nebulized magnesium sulfate can improve the clinical score so it may have additive effect to reduce symptoms during hospitalization